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ThegeneSCN9A is responsible for threehumanpaindisorders.Non-
sensemutations cause a complete absence of pain,whereas activat-
ing mutations cause severe episodic pain in paroxysmal extreme
pain disorder and primary erythermalgia. This led us to investigate
whether single nucleotide polymorphisms (SNPs) in SCN9A were
associatedwith differing pain perception in the general population.
We first genotyped 27 SCN9A SNPs in 578 individuals with a radio-
graphic diagnosis of osteoarthritis and a pain score assessment. A
significant association was found between pain score and SNP
rs6746030; the rarer A allele was associated with increased pain
scores compared to the commoner G allele (P = 0.016). This SNP
was then further genotyped in 195 pain-assessed people with scia-
tica, 100 amputeeswith phantompain, 179 individuals after lumbar
discectomy, and 205 individuals with pancreatitis. The combined P
value for increasedAallelepainwas0.0001 in thefivecohorts tested
(1277 people in total). The two alleles of the SNP rs6746030 alter the
coding sequenceof the sodiumchannelNav1.7. Eachwas separately
transfected intoHEK293cells andelectrophysiologicallyassessedby
patch-clamping. The two alleles showed a difference in the voltage-
dependent slow inactivation (P = 0.042)where theA allelewould be
predicted to increase Nav1.7 activity. Finally, we genotyped 186
healthy females characterized by their responses to a diverse set
of noxious stimuli. The A allele of rs6746030 was associated with
an altered pain threshold and the effect mediated through C-fiber
activation. We conclude that individuals experience differing
amounts of pain, per nociceptive stimulus, on the basis of their
SCN9A rs6746030 genotype.
Nav1.7 | nociception | pain | SCN9A | single nucleotide polymorphisms
The ability to sense noxious events (nociception) is of profoundimportance to complex organisms, as shown by its presence in
animals as diverse as snails, reptiles, amphibians, and mammals
(1–4). As a sense, pain serves as an adaptive mechanism that
protects us from tissue damage by alerting us to events that are
capable of producing injury and evokes behaviors that promote
tissue healing. However, the development of maladaptive persis-
tent pain states in response to tissue injury is common, with one in
six adults suffering from a chronic pain condition (5). The search
for effective analgesics with acceptable side effects has long been
the goal of doctors and biomedical researchers. Because current
therapies have limited efficacy, with up to 50% of treated subjects
receiving inadequate pain relief (6), there exists a significant need
to develop better therapies.
Our understanding of the neurobiology of pain pathways has
accelerated substantially since the mid-20th century (7). Within the
last decade the molecular biology of membrane receptors and
channels that respond to pain-provoking stimuli have been identi-
fied and characterized, e.g., the TRPV1 heat receptor (which is also
activatedby capsaicin, theactive ingredient inhot chilli peppers) (8).
More recent findings have demonstrated the unexpected impor-
tance of other molecules in pain appreciation in humans, including
catechol-O-methyltransferase (COMT)and tetrahydrobiopterin (9,
10), which modulate nociceptive and inflammatory pain, and
SCN9A (11–17), mutations of which can result in syndromes of
either excessive pain or insensitivity to pain.
SCN9A encodes the α-subunit of the voltage-gated sodium chan-
nel Nav1.7, which is expressed at high density in nociceptive neurons
(18). A number of clinical effects of Nav1.7 mutations have been
reported in recent years (Fig. 1) (11–13, 15). Primary erythermalgia
(OMIM 133020) and paroxysmal extreme pain disorder (OMIM
167400) are distinct syndromes associated with abnormal attacks of
severe pain (19, 20), and are caused by SCN9A mutations that
increaseNav1.7 channel activity (20). Nonsensemutations in SCN9A
lead to a lifelong inability to sense pain in the autosomal recessive
condition channelopathy-associated insensitivity to pain (OMIM
243000) (11, 21). With the exception of having never felt pain and
being anosmic, affected individuals are completely normal, suggest-
ing that Nav1.7 is a vital component in the perception of pain in
humans and that functions of the protein associated with its expres-
sion outside the nociceptive system are redundant. The data raise the
possibility that almost complete analgesia may be possible by tar-
geting this ion channel in humans.
Although subjects with major pain phenotypes are very rare, a
role for more common polymorphisms in determining inter-
individual pain perception is beginning to emerge (22). Within
this context there are multiple single nucleotide polymorphisms
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(SNPs) in the human SCN9A gene, raising the possibility that
allelic differences in this gene might influence nociception in the
general population. In this study we have investigated the associ-
ation between SCN9A SNPs and pain perception in five cohorts of
subjects with a range of pathological conditions for whom we had
individual measures of reported pain and corresponding DNA
samples for genotyping. The study was performed to establish
whether common polymorphisms in SCN9A have an effect on
nociception, and if so, what might be the pathophysiological basis
as assessed by measurements both of in vitro Nav1.7 channel
function and of pain perception in normal subjects.
Results
Association Analysis of Nav1.7 Variants with Pain Cohorts. In an
initial cohort of 578 subjects with osteoarthritis (OA) (see also SI
Subjects and Methods and Fig. S1), we screened 27 SNPs in SCN9A
and found that 5 showed a significant association with the pain score
in a linear regression model that included adjustments for age, gen-
der, body mass index (BMI), and age–gender interaction (Table 1):
rs6432896, P= 0.048; rs7604448, P= 0.036; rs10930214, P= 0.027;
rs6746030, P = 0.016; and rs7595255, P = 0.02. The corresponding
allele frequencies and the unadjusted mean pain scores for all SNPs
divided according to genotype are shown in Tables S1 and S2.
Examination of the pair-wise linkage disequilibrium data suggests
that of thefive SNPs that exhibited a significant associationwith pain,
the last four were in linkage disequilibrium. The magnitude of the
effect on the pain score ranged from 0.44 to 0.76/rare allele [on the
Western Ontario and McMaster Osteoarthritis Index (WOMAC)
scale of 0–20] with the largest effect and lowest P value being
observed with the amino acid changing SNP rs6746030.
Four of the SNPs that were significantly associated with the pain
score are located in introns and are not changes that commonly
affect mRNA stability or splicing, nor do they form part of con-
served motifs. SNP rs6746030, however, is located in exon 18 and
affects the amino acid at position 1150 of Nav1.7, with the more
frequent allele encoding an arginine (NaV1.7–1150R) and the less
frequent encoding a tryptophan (NaV1.7–1150W). Because of its
strongest effect in the regression analysis and the predicted amino
acid change, SNP rs6746030 was selected for investigation in
additional pain cohorts.
Analysis of a Finnish cohort, comprising 195 individuals with
sciatica, showed a significant association of rs6746030 with a Visual
AnalogPainScore (P=0.039) under a recessive geneticmodel. In a
group of 100 Danish amputees, using the same recessive model,
rs6746030 was found to be significantly associated with phantom
pain experience (P = 0.011). In both cohorts, as in the individuals
with osteoarthritis, the minor A allele was associated with a greater
experience of pain. Furthermore, in a cohort of 179 individuals with
lumbar root pain the pain score also tended to increase with the
number of minor A alleles at SNP rs6746030 (Table S3 and SI
Results). The mean adjusted pain scores for the different genotypes
were 0.47 (G/G), 0.65 (G/A), and 0.97 (A/A) on a scale with values
ranging between−1.3 and 2.7, giving a p value for an additivemodel
analysis of 0.088.
We also investigated a cohort of patients with pancreatitis pain,
but found no difference in the distribution of rs6746030 alleles
either between patients and controls or between patients who had
or had not needed surgery to control pain (SI Results and Table
S4). For those patients experiencing ongoing pain, however, both
the mean pain score and the composite pain score were higher in
subjects with the minor A allele than in those without the A allele,
although these differences were not statistically significant.
Wenoted that ineach individual study the trendwas for theminor
A allele to be associated with a greater experience of pain. We
therefore generated a combined P value of all five cohorts, using a
modification of the inverse normal method (23). The combined P
value for thefive cohorts was 0.0001 (Table 2), indicating that across
a variety of study conditions, the degree of pain experienced was
strongly dependent on an individual’s rs6746030 genotype.
Functional Analysis of Nav1.7 Variants. To investigate the functional
effects of the rs6746030 SNPs, we compared the electrophysiological
propertiesofNav1.7 channels containing the twodifferent aminoacid
variants at position 1150. NaV1.7–1150R and NaV1.7–1150W were
coexpressed with the β1 and β2 subunits of voltage-gated sodium
channels in HEK293 cells, and the properties of the expressed
channels were investigated in whole-cell patch-clamp recordings by
Fig. 1. Schematic of the SCN9A gene showing the position of known mutations (arrows) that result in human disorders of pain appreciation. SCN9A encodes
the voltage-gated sodium channel, Nav1.7, which is composed of four repeating domains, each comprising six transmembrane segments. The regions of the
gene that encode the transmembrane segments and the inactivation domain are indicated (see colored key).











using a range of protocols to evaluate different parameters of
channel activation and inactivation (Fig. 2 and SI Subjects and
Methods). No differences between the variants were observed in the
peak current amplitude or the voltage dependence and time con-
stants of activation and fast inactivation. However, inactivation of
voltage-gated sodium channels involves at least two inactivated
states, the slower of which is evident only after prolonged depola-
rizations. To analyze slow inactivation, we measured the current
amplitude after a 10-s depolarization to different voltages and a
subsequent short hyperpolarization step to recover only the fast
inactivating states. Slow inactivation occurred at more positive
potentials than fast inactivation and reached only∼80%. Although
the extent of slow inactivation was similar for both channel variants,
we observed a significantly steeper voltage dependence of NaV1.7–
1150W compared with NaV1.7–1150R currents (k= 10.7± 0.4 mV
and 13.7 ± 1.2 mV, respectively; n= 7 each; P= 0.042; Fig. 2G).
Is SNP rs6746030 Associated with Pain Thresholds in Normal
Individuals? To investigate the contribution of specific nocice-
ptive pathways thatmightmediate theeffect of theminorAallele of
SCN9A, we analyzed data from a cohort of 186 healthy European–
American females who were free of pain at the time of examination
andwhowerephenotypedwithadiverse setofexperimentalnoxious
stimuli (9). Minor A allele carriers showed a trend to be more
sensitive to all types of experimental stimuli, although only those
procedures that evoked predominately C-fiber–mediated heat pain
reached statistical significance (Figs. S2 and S3 and Table S5).
Discussion
Our data show that a commonpolymorphism in theSCN9A gene is
strongly associated (P=0.0001) with pain perception in a range of
pathological conditions. Of five SCN9A SNPs found initially to be
significantly associated with the level of pain experienced from
osteoarthritis, only rs6746030 results in a coding change whereas
the other four are not predicted to be detrimental. The minor
allele of rs6746030 occurs at a frequency of ∼10%, is associated
with increased pain perception, and results in an amino acid
change from arginine to tryptophan at position 1150 of Nav1.7.
This residue lies in the intracellular loop between transmembrane
domains II and III ofNav1.7, a region of the channel with unknown
function. However, 1150R is an evolutionarily conserved amino
acid (Fig. S4), suggesting that it could contribute to the normal
function of Nav1.7.
The WOMAC self-administered questionnaire specifically docu-
ments pain relevant to osteoarthritis and is validated for determining
pain levels, but relies on a subjective assessment by the patient. All
suchmeasuresofpain severity are intrinsically imprecisebecause they
necessarily rely on subjective reporting using pain scales such as the
WOMAC questionnaire or the Visual Analog Pain Scale. The con-
sequent variability in quantifying pain is a major contributor to
reducing the power of this type of study. Nevertheless, the observed
difference in pain intensity felt by homozygouswild-type subjects and
carriers of the genetic variants is≈0.8WOMACpoints per rare allele
(on the WOMAC pain scale of 0–20). This compares with a mean
improvement of opiates over placebo in OA pain studies of≈1 point
(on an 11-point scale) (24). The results suggested that carriers of the
rs6746030 A allele in the general population would be expected to
experience more pain for a given stimulus than their fellows.
Further evidence that theminorAalleleofSCN9ASNPrs6746030
influences the degree of pain experienced comes from the studies in
people with sciatica, amputees with phantom limb pain, and patients
with postdiscectomy lumbar root pain (same trend but not reaching
significance). We found no association between pain experienced in
pancreatitis and SNP rs6746030. However, when the combined P
value was calculated across all studies, a p value of 0.0001 was pro-
duced, confirming a significant contribution of the rs6746030Aallele
to human pain experience. Furthermore, when pain responses to a
diverse set of experimental procedures were examined, the associa-
tionof the rs6746030aallelewas found tobemost strongly associated
with C-fiber activation. This result suggests that C-fiber activation,
which underlies the sensation of diffuse, dull, aching pain represents
the nociceptive pathwaymediatingA-allele–driven clinical pain (22).
Both clinical and experimental pain studies support an additive
model for the effect of rs6746030 alleles, withmost pain being felt by
carriers of theAAgenotype and the least painwith theGGgenotype.
During detailed electrophysiological assessment of Nav1.7–
1150R and 1150W currents, we observed a statistically significant
difference in the steepness of the voltage dependence of slow inac-
Table 2. Results for the five clinical cohorts showing the effect












1. Osteoarthritis 578 A 0.016*
2. Sciatica 195 A 0.039*
3. Postamputation 100 A 0.011*
4. Postdiscectomy 179 A 0.088
5. Chronic
pancreatitis
205 A = G 0.732
6. Meta-analysis 1257 A 0.0001*
*Cohort results reached statistical significance.
Table 1. Linear regression analysis for pain score (trend effect











rs4447616 −0.32 −0.77 0.13 0.1598
rs10171225 0.28 −0.26 0.81 0.3094
rs4286289 −0.08 −0.56 0.41 0.7595
rs4605385 0.09 −0.48 0.67 0.7464
rs6432896 0.44 0.00 0.88 0.0476
rs12994338 0.08 −0.42 0.58 0.7546
rs13017637 −0.18 −0.63 0.27 0.4375
rs12620053 0.10 −0.35 0.55 0.6623
rs12619987 −0.02 −0.69 0.64 0.9422
rs11688164 −0.05 −0.67 0.58 0.8845
rs13402540 0.18 −0.27 0.62 0.4323
rs6747673 −0.03 −0.46 0.40 0.8822
rs6432894 −0.05 −0.51 0.41 0.8335
rs4453709 −0.03 −0.47 0.41 0.8918
rs4443014 0.34 −0.18 0.85 0.2019
rs4561679 0.60 −0.06 1.27 0.0754
rs4371369 0.33 −0.11 0.77 0.1431
rs7604448 0.63 0.04 1.21 0.0361
rs10930214 0.52 0.06 0.99 0.0266
rs6746030 0.76 0.14 1.38 0.0158
rs12621853 0.08 −0.51 0.68 0.7853
rs17748381 −0.36 −1.08 0.36 0.3226
rs10170041 0.30 −0.14 0.74 0.1791
rs16851799 −0.02 −0.46 0.43 0.9457
rs7595255 0.73 0.11 1.34 0.0210
rs6432885 −0.25 −0.68 0.18 0.2529
rs3750904 1.44 −1.84 4.72 0.3888
Significant results are shown in boldface. “Mean effect size” is the mean
difference in pain score per additional rare allele, e.g., AA versus Aa and Aa
versus aa calculated from the regression analysis. “P value” is based on a
linear regression analysis for pain score trend effect per rare allele adjusting
for age, gender, body mass index, and age/gender interaction.
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tivation. The steeper slope of Nav1.7–1150W currents (encoded by
the minor A allele) would tend to make these channels less suscep-
tible to slow inactivation at potentials negative to −35 mV. Because
slow inactivation of Nav1.7 is believed to play a role in setting the
threshold andfiring frequencyof nociceptive neurons, the lesser slow
inactivationof the rareAallelic variant at voltages close to the resting
potential would tend to make the neurons more sensitive to painful
stimuli (25). However, the observed biophysical effect is rather small
and might be insufficient to explain the associated phenotype,
because alterationof the slow inactivationof theNav1.7 conductance
alone in theabsenceof altered voltage-dependent activation failed to
change the firing properties in a computer model of nociceptive
neurons (26). It is important to note that another recent study failed
to observe a change in voltage dependence of slow inactivation, but
instead reported a small depolarizing shift in the voltagedependence
ofactivation forNav1.7–1150Wcompared toNav1.7–1150Rcurrents
(27). By contrast, most Nav1.7 mutations associated with hyper-
excitability and erythromelalgia have been reported to shift the
voltage dependence of activation in the opposite, hyperpolarizing
direction (26, 28). Nevertheless, Nav1.7–1150W produced hyper-
excitability when expressed in small dorsal root ganglion neurons
(27), a finding that is consistent with the clinical results presented
here. The exact mechanism by which the minor A allele enhances
pain sensitivity therefore remains unclear and might involve factors
not present in the heterologous expression system, factors that affect
expression, processing, or interaction of the Nav1.7 protein in no-
ciceptive neurons.
Thework presented here provides additional evidence that human
pain experience is under genetic influence. Although small associa-
tion studies have limitations, and each of these studies will need
replication in independent cohorts, the trend for carriers of theminor
A allele to experiencemore pain in a variety of nociceptive situations
is striking and supportedby a strong combinedP valueof 0.0001. Pain
experienced in common conditions such as osteoarthritis and back
pain is influencedbydisease severity, pain sensitivity, andresponses to
analgesics. The contribution of each common polymorphic genetic
variant with common pain conditions is expected to be relatively
modest, unlike the major effects observed in Mendelian familial
diseases such as channelopathy-associated insensitivity to pain (22).
Our results suggest that, like COMT andGCH1, SCN9A is a sub-
stantial contributor to human pain sensitivity and clinical pain con-
ditions (9). Activating mutations in SCN9A lead to severe episodic
pain, inactivatingmutations cause a complete absenceof pain, andwe
nowcan show that SNPrs6746030quantitatively alterspain sensitivity
and pain experienced in common conditions such as osteoarthritis
and spinal nerve root pain. The findings support the idea that phar-
macological substances that modify the function of SCN9A (Nav1.7)
wouldbepotentially useful in treating these conditions.As individuals
appear to have differing genetic susceptibilities to pain, future studies
Fig. 2. BiophysicalpropertiesofNaV1.7–1150RandNaV1.7–1150Wcurrents. (A) Current responses to50-msvoltagestepsof5-mVincrementsbetween−70and+40
mV from a holding potential of−100mV in a whole-cell voltage clamp recording applied at 0.5 Hz for a HEK293 cell expressing Nav1.7–1150W. (Inset) The voltage
pulse protocol. (B) Current–voltage relationship of the peak currents normalized for cell size [picoamperes per picofarad (pA/pF)] obtainedusing the experimental
setup shown inA. Lines representfits of the datawith a Boltzmann equation:■, NaV1.7–1150W [V0.5 =−26.0± 2mV, k = 4.8± 0.4mV,Vrev = 64± 2mV (n = 17)];○,
Nav1.7–1150R [V0.5 =−29.0± 1mV,k =4.4± 0.3mV,Vrev = 62± 2mV (n=10)]. (C) Voltagedependenceof theactivation time constant τm (left) and inactivation time
constant τh (right), obtained byfitting current traces elicited by depolarizing pulses from−40 to +40mVof 50ms duration from a holding potential of−100mV (as
shown inA) with a Hodgkin–Huxley m3hmodel (for voltage gated sodium channels).■, NaV1.7–1150W, O, Nav1.7–1150R. (D) Voltage dependence of the steady-
state inactivation of NaV1.7–1150W currents was measured by holding the membrane potential for 500 ms at conditioning voltages from −120–0 mV (at 5-mV
increments)before steppingtoa testpulseat−10mVfor50ms. (Inset) Thevoltagepulseprotocol,whichwasappliedat0.5Hz.Only thecurrent responses to thetest
pulse are shown. (E) Peak currents obtained as in Dwere normalized to the maximum peak current and plotted against the holding potential applied during the
conditioning pulse. Lines represent afit of the datawith a Boltzmann equation:■, NaV1.7–1150W [V0.5 =−73.0± 2mV, k = 5.5± 0.2mV (n = 17)]; O, Nav1.7–1150R
[V0.5 =−73.0±2mV,k=5.4±0.2mV (n=10)]. (F) Voltagedependenceof the slow steady-state inactivationofNaV1.7–1150Wcurrentswasmeasuredbyholding the
membrane potential for 10 s at conditioning voltages from −120mV to 0 mV (at 5-mV increments) before stepping up for 100ms to −120mV to recover channels
in the fast inactivated state followed by a test pulse at−10mV for 20ms. (Inset) The voltage pulse protocol. Only the current responses to the test pulse are shown.
(G) Peak currents obtained as in fwere normalized to themaximumpeak current and plotted against the holding potential applied during the conditioning pulse.
Lines represent afit of thedatawithaBoltzmannequation:■, NaV1.7–1150W[V0.5=−35±3mV,k=11±1mV,A2=15±2%(n=7)];O,Nav1.7–1150R [V0.5= -37±5
mV, k = 14 ± 1 mV; A2 = 18 ± 3% (n = 7)].











should be directed toward understanding whether responsiveness to
different classes of analgesics is also genetically determined.
Subjects and Methods
Study Subjects. For further descriptions of the study subjects, see SI Subjects
and Methods. Relevant ethical approval was obtained for the inclusion of all
individuals in each study cohort.
Cohort 1: Osteoarthritis. Clinical information and DNA samples were available
on 578 individuals from four OA clinical trials (see SI Subjects and Methods)
sponsored by Pfizer. Individuals had radiographically confirmed osteo-
arthritis of either knee or hip, and all were self-reported as Caucasian.
Participants had a WOMAC pain score—a visual analog scale that has been
used extensively in patients with osteoarthritis of the hip or knee to judge
discomfort and gauge eligibility for surgery.
Cohort 2: Sciatica pain. A total of 195 Finnish patients with sciatica symptoms
were recruited fromOuluUniversityHospital in anextension of a previous study
(29). Inclusion criteria included unilateral pain radiating from the back to below
the knee. All patients were confirmed to have a lumbar disk herniation con-
cordant with the symptoms by MRI. A rating on the Visual Analog Pain Scale at
baseline was used as the primary outcome for the analysis.
Cohort 3: Phantom pain. A total of 100 Danish amputees with upper and/or
lowerlimbamputationswerestudied;allwereCaucasian.Theprimaryphenotype
was the experience of phantom pain, graded as (1) never, (2) previously, or (3)
currentlywithfurthersubdivisionofthosewhoexperiencedphantompainwithin
the last month according to the frequency, duration, and intensity of
pain episodes.
Cohort 4: Lumbar root pain. A total of 179 Caucasians from the Maine Lumbar
Spine Study were assessed for pain on a seven-point score one year after
lumbar discectomy surgery (30). The primary endpoint—persistent leg pain
over the first year—was determined by an area-under-the-curve score cal-
culated from four questions about leg pain collected at 3, 6, and 12 months.
Cohort 5: Chronic pancreatitis. A total of 205 Caucasians with chronicpancreatitis
were compared with a control group of 168 healthy adults. Chronic pancreatitis
was diagnosed according to established criteria (31). Pain was measured by (1) a
modified version of the Gastrointestinal Symptoms Questionnaire and (2) a
validated composite pain score that also included the pain pattern, pain per-
ception during the last attack, usage of morphine-like analgesics, and whether
surgery for pancreatic pain had ever been necessary.
Cohort 6: Pain-free females. A total of 186 healthy European–American pain-
free females were phenotyped and genotyped. We restricted our analysis to
Europeans to avoid the possible effect of population stratification. Each
enrolee was quantified for responsiveness to a set of 13 noxious stimuli
applied to various anatomical sites (9, 32).
Genotyping. SNPs were identified in the SCN9A gene from the Hapmap
database and chosen for genotyping in the OA cohort on the basis of their
allele frequency, potential to have a functional effect, confirmation as a real
SNP, and linkage disequilibrium coverage of the gene (Table S1). Genotyping
was performed using primer extension methodology or TaqMan assay fol-
lowing the manufacturer’s instructions (Applied Biosystems).
Statistical Analysis of Pain Phenotypes. For OA cohort 1, an initial analysis was
undertaken to establish the importance of covariates, including gender, age,
and each study. To evaluate SNP associations, separate models were run with
each SNP term added to the base model. Genotype effect was initially
assessed in a codominant genetic model and compared with models that
included a term for deviation from additivity due to either a dominant or a
recessive mechanism (SI Subjects and Methods).
Calculation of Combined P Value. Amodification of the inverse normalmethod
(23) was used to combine association P values for the clinical cohorts. The
modification takes into account the direction of the phenotypic effect. This is
achieved by converting two-sided P values (p) into one-sided (q), noting the
direction of the association with the allele A. If the direction of association is
positive, thenq=p/2;otherwise,q=1−p/2.After thesevaluesare combined into
anoverall P value, the result is doubled if the combined value is smaller than 1/2;
otherwise, it is subtracted from 1 and then doubled. Overall and Rhoades (34)
proposed a similar approach based on the Fisher combinationmethod. Because
the effect direction is not chosenbeforehand, they recommend evaluatingboth
directional hypotheses in turn, computing two one-sided P values and then
doubling the minimum value (33). However, this is not needed with Stouffer’s
approach because of the symmetry of the inverse normal transformation: the
two one-sided P values are the samewith this approach, once convertedback to
the two-sided. Stouffer’s method allows P values to be weighted (34). The
weights were set to the square roots of the sample sizes.
Electrophysiology. Both rs6746030 alleles were generated in a cDNA clone
encoding the most common SCN9A splice variant found in dorsal root ganglia
(NM_002977) (18) using the QuikChange XL site-directed mutagenesis kit (Stra-
tagene). HEK293A cells (QBiogene) were transiently transfected with plasmids
expressingeitherNaV1.7–1150R(commonallele)orNaV1.7–1150W(minorallele)+
DsRed2 and SCN1B + SCN2B + EGFP using lipofectamine 2000, and experiments
were performed 2–3 days after transfection on cells positive for red and green
fluorescence, as previously described (11). Briefly, electrodes had resistances of
2.5–3 MΩ when filled with pipette solution, and 70% series resistance compen-
sation was used throughout. Currents were zero and leak subtracted using a p/4
protocol. The bath solution contained (mM): 3 KCl, 140 NaCl, 2 CaCl2, 1 MgCl2, 10
hepes, and 1 glucose (pH 7.4 with NaOH). The patch pipette solution contained
(mM): 107 CsF, 10NaCl, 1 CaCl2, 2MgCl2, 10Hepes, 10 TEACl, and 10 EGTA (pH7.2
with CsOH). See SI Subjects andMethods for additional details.
URLs. SNPs are detailed in dbSNP at http://www.ncbi.nlm.nih.gov/SNP/. Genes
and the human genome can be viewed and accessed at UCSC Bioinformatics
Genome Browser (http://genome.ucsc.edu/) and at the Human Mendelian
disease database (OMIM) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=OMIM&itool=toolbar).
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